Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
about
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemiaTreatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibRandomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaMonitoring response and resistance to treatment in chronic myeloid leukemia.Chronic myeloid leukemia: mechanisms of resistance and treatment.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureThe bone marrow microenvironment as a sanctuary for minimal residual disease in CML.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Contribution of tumoral and host solute carriers to clinical drug response.Suboptimal responses in chronic myeloid leukemia: implications and management strategiesManagement of imatinib-resistant patients with chronic myeloid leukemia.A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemiaChronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.Therapeutic drug monitoring for imatinib: Current status and Indian experience.Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.Treatment of chronic myeloid leukemia when imatinib fails.New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.Treatments for chronic myeloid leukemia: a qualitative systematic review.Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.Chronic myeloid leukemia: overview of new agents and comparative analysis.Management options for refractory chronic myeloid leukemia: considerations for the elderly.Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901.Will kinase domain mutations dictate the terms….Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance.High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
P2860
Q27028181-689107C7-7070-49CC-90A4-B91AABFF1FF3Q27851628-1613DDBF-8841-42A1-8B13-C69EED6BDC30Q28477798-AC9D2E5E-A52F-4E09-A74C-FD2A19E78DF0Q33391185-5C26CC04-19FE-457C-8AA9-CF0EFAFF4BCDQ33408184-32B7AE0D-D003-4064-A1B4-187172E5AF9DQ33878636-CD656AE0-649A-419C-8EB9-DDF14D226AF1Q34272962-693FD2C1-0306-415A-9F1D-4F4B4DC9AFEFQ34522789-A3D30BF0-943B-4C30-9CEC-D4189747F218Q34761663-11B19599-ECF7-4656-93CE-C9E504EDABD0Q35595795-EE75A5A6-D341-4851-AAF5-9B2B9638DE9DQ35596200-C6D5C38F-6754-4B9F-9C45-1015A15C96EEQ35773205-B6823FAC-1B71-44E7-995A-C00769F8750BQ35930616-6237DC9E-723B-4ED5-8FA3-8F55D973D9E8Q35946876-8938230E-9E9A-40AF-8874-235F97E10090Q36144079-2D03D304-F349-44AE-9668-B24D29F1000AQ36776423-44E8AEA4-5E88-4557-B63B-9921CF4BEFBCQ37073009-2DEEEFA9-E934-458C-A667-44F4E51850A3Q37163550-463F30A0-A1E8-4473-9299-12D93CC4CD9AQ37428659-E5E6AE2A-BD09-41E7-AFC4-28E9A7606658Q37505017-9F0BF5BC-B0B0-4158-9A5B-101372B7BB80Q37517632-83D99F69-7852-4988-B83A-7151E0C2FA6FQ37607094-BF72B500-B6BB-41B9-B8CF-BFE05F35B20FQ37791429-016BA0EA-C91F-45BB-97AD-0809A26A31FDQ37827875-EBA126E1-54BB-4D00-AB86-7B75F3551120Q37836938-56154AFF-28C3-4496-B6BF-7C0D8597403DQ37888714-BFAEB706-4573-493A-879E-C4202FC1F6ACQ37896606-CAEA7DB8-AE5C-432B-9E1E-F3FAEDF5036FQ38037079-A37F8B93-A2F3-4231-9F41-AC396F6637F9Q38037648-D67DE0A0-928C-4B83-AB11-75B30CE65128Q38097728-DE12F4DC-7CB7-43D4-A779-9FBF06D87F02Q38101471-1BD1AE27-1300-485B-96C9-47805F9DA676Q38436037-9508A7C6-5607-4FE7-B4E1-ED7736F02825Q39116591-B75C9D9C-66BA-499D-8346-00AC8F9DBDABQ39251672-D883840E-D64D-4789-A8A1-37365C78E62EQ41892279-1E70E423-C7B1-4890-8446-FBF0E2ACC2BEQ42409714-BF880782-9F9F-484C-B287-859FC2EC14CCQ44285076-96477941-D599-4A1D-A180-C9C8D28E04CEQ54596369-31C3E2E5-D27C-48D6-A31D-B49E0D94EE1B
P2860
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Efficacy of imatinib dose esca ...... oid leukemia in chronic phase.
@ast
Efficacy of imatinib dose esca ...... oid leukemia in chronic phase.
@en
type
label
Efficacy of imatinib dose esca ...... oid leukemia in chronic phase.
@ast
Efficacy of imatinib dose esca ...... oid leukemia in chronic phase.
@en
prefLabel
Efficacy of imatinib dose esca ...... oid leukemia in chronic phase.
@ast
Efficacy of imatinib dose esca ...... oid leukemia in chronic phase.
@en
P2093
P2860
P50
P356
P1433
P1476
Efficacy of imatinib dose esca ...... oid leukemia in chronic phase.
@en
P2093
Francois Guilhot
International Randomized Study of Interferon and STI571 (IRIS) Investigators
Manisha Mone
Marc Rudoltz
Stephen G O'Brien
Tillmann Krahnke
P2860
P304
P356
10.1002/CNCR.24066
P407
P577
2009-02-01T00:00:00Z